High dose rate brachytherapy in primary and recurrent tongue cancer
Journal of the Korean Association of Maxillofacial Plastic and Reconstructive Surgeons
;
: 470-476, 2006.
Article
in Korean
| WPRIM
| ID: wpr-784706
ABSTRACT
dose rate brachytherapy(LDR) has been effective modality for treatment of oral cancer. But the disadvantage of LDR is radioexposure of medical staff. To overcome this problem, high dose rate(HDR) brachytherapy has been developed. Our study evaluates the outcomes of patients with tongue cancer as treated by HDR brachytherapy. Between 2002 and 2005, eight patients with carcinoma of the tongue were treated with HDR brachytherapy. Five patients had AJCC stage I or II disease and the remaining three patients had AJCC stage III or IV. The male-to-female ratio was 26 and the mean age was 60.1 years (range 21-80 years).The median follow-up time was 23.8 months (range 7-55 months). There was no local failure until now. Three patients showed some complications. Two patients showed soft tissue necrosis. There was no bone sequela in all cases. Our experience in treating tongue cancer with HDR brachytherapy is encouraging, because it gave a satisfactory local control. Prospective studies are necessary to delineate the optimum indication for this treatment modality and long-term outcome.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Tongue
/
Brachytherapy
/
Mouth Neoplasms
/
Tongue Neoplasms
/
Follow-Up Studies
/
Medical Staff
/
Necrosis
Type of study:
Observational study
/
Prognostic study
Limits:
Humans
Language:
Korean
Journal:
Journal of the Korean Association of Maxillofacial Plastic and Reconstructive Surgeons
Year:
2006
Type:
Article
Similar
MEDLINE
...
LILACS
LIS